Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T40075 |
PROTAC BRD4 Degrader-13
PROTAC BRD4 Degrader-13 |
||
PROTAC BRD4 Degrader-13 (compound 9d) is a bioactive compound that functions as a proteolysis targeting chimera (PROTAC), linking ligands for von Hippel-Lindau and BRD4 proteins. In the context of PC3 prostate cancer cells, this compound effectively degrades the BRD4 protein through conjugation with STEAP1 and CLL1 antibodies. The degradation of BRD4 protein is achieved with remarkable potency, exhibiting a DC 50 of 0.025 nM and 6.0 nM when combined with STEAP1 and CLL1 antibodies, respectively. | |||
T31221L |
dBRD9 HCl
dBRD9 HCl(2170679-45-3 Free base) |
Epigenetic Reader Domain | Chromatin/Epigenetic |
dBRD9 HCl 是一种PROTAC,包含cereblon E3连接酶配体与BRD9抑制剂BI 7273。dBRD9 HCl 是有效和选择性的BRD9降解剂,在MOLM-13细胞中IC50的为56.6nM。dBRD9 HCl 在浓度高达5μM 时不会降解BRD4或BRD7。dBRD9 HCl 在人AML 细胞系中显示出抗增殖作用。 | |||
T11291 |
FKBP12 PROTAC dTAG-13
dTAG-13 |
Epigenetic Reader Domain; PROTACs | Chromatin/Epigenetic; PROTAC |
FKBP12 PROTAC dTAG-13 (dTAG-13) is a degrader of FKBP12F36V with expression of FKBP12F36V in-frame with a protein of interest. FKBP12 PROTAC dTAG-13 (dTAG-13) also is a selective degrader of BET bromodomain transcriptional co-activator BRD4 by bridging BET bromodomains to an E3 ubiquitin ligase CRBN. FKBP12 PROTAC dTAG-13 (dTAG-13) is a PROTAC-based heterobifunctional degrader. |